BIOMERICA’S EZ DETECT™ TEST TO BENEFIT FROM LASTEST STUDY RECOMMENDING AT-HOME COLORECTAL SCREENING TESTS
-- At-Home Fecal Occult Blood Tests, Such As Offered By Biomerica, Are Recommended Over Doctors
Office Single Sample Tests --
NEWPORT BEACH, California, January 20, 2005 -- Biomerica, Inc. (OTC BB: BMRA) today announced the importance of a major 13 medical center study, published in the current issue The Annals of Internal Medicine, regarding the use of the single in-office test used by doctors. The study concludes that the single in-office fecal occult blood test (FOBT) is a poor screening method for colorectal neoplasia and that tests given to patients to do on their own at home were far more reliable.
“What we found is that it was pretty worthless,” said Dr David Lieberman (one of the study’s authors) regarding the in-office single test used by doctors. “It’s a wake-up call that we should not be relying on this test,” he told the Associated Press.
An accompanying survey of physicians (funded by the National Cancer Institute and the Centers for Disease Control and Prevention) and also published in the Annals of Internal Medicine, said one possible reason for using the doctors office tests was concern that patients won't complete the home tests. The completion rate varies greatly, with the median between 40 and 50 percent.
"My guess is that many physicians may not be aware that the in-office test is such a poor test," said Marion R. Nadel, a CDC epidemiologist who worked on the survey. Nadel said doctors should be trying to find more ways to get patients to complete the home test.
Biomerica’s patented screening test EZ Detect™ is the simplest at home test available to detect fecal occult (hidden) blood. EZ Detect is the only FDA cleared test that does not requiring no handling of stool or dietary restrictions. The EZ Detect pad is tossed into the toilet after a bowel movement. A change in the pad’s color to blue/green, which will appear within two minutes, indicates the presence of blood in the stool. If a positive result occurs, an appointment with a physician should be made as soon as possible to determine the cause of bleeding.
“For years we have been stressing the benefits of at-home FOBT testing. This study proves that the benefits are very substantial,” said Zackary Irani, Biomerica CEO
Cancer of the colon and rectum is a “quiet killer,” killing more than 65,000 Americans annually with another 130,000 diagnosed with the disease. People detected with colon cancer in its earliest stage had a five-year survival rate of 90 percent, compared to an 8 percent survival rate of those diagnosed with the cancer after it had progressed. Only 37 percent of all colorectal cancers are detected at an early stage, however, because too few people regularly screen for it. The American Cancer Society recommends that all persons over age 50, or those with a family history of colorectal problems, perform a stool blood test at least once a year.
# # #
About Biomerica (OTC BB: BMRA)
Biomerica, Inc. (http://www.biomerica.com) is a global medical technology company, based in Newport Beach, CA. The Company’s diagnostics division manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians’ offices for the early detection of significant medical conditions and serious diseases.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, increased sales